Xuedong Liu, a University of Colorado Boulder professor of biochemistry, has been named a member of the 2024 Class of Fellows by the National Academy of Inventors (NAI), the group recently announced.
Liu is one of an elected group of 170 “exceptional inventors” honored in 2024.
The 2024 cohort of fellows exemplifies the academy’s belief that groundbreaking innovation knows no bounds and inventors can be found everywhere, the NAI said, adding that the honorees represent 39 U.S. states and 12 countries. “This year’s class of NAI Fellows represents a truly impressive caliber of inventors. Each of these individuals are tackling real-world issues and creating solutions that propel us into the future. Through their work, they are making significant contributions to science, creating lasting societal impact and growing the economy,” said Paul Sanberg, NIA president. Liu’s laboratory works to understand the fundamental mechanisms underlying cell-cell communication. Aberrations of normal signaling networks can lead to human diseases such as cancer. The Liu laboratory is developing novel therapeutic solutions for treating cancer and neurodegenerative diseases.
Liu is co-founder of OnKure Therapeutics (Nasdaq: OKUR) and founder of Vesicle Therapeutics. His lab discovered and patented a profile-specific histone deacetylase inhibitor, which has entered phase II clinical trials, and a new type of drug delivery system.
